source
- Novartis encounters setbacks while AI firm Anthropic searches for a dealmakerThe latest Endpoints Weekly edition highlights a difficult period for Novartis, noting that the company is facing a series of setbacks. Details of the challenges are not provided, but the report s…
- GSK’s risvutatug rezetecan shows 18.5-month median overall survival in phase 3 SCLC trialGSK, together with Chinese partner Hansoh Pharma, reported results of its antibody‑drug conjugate risvutatug rezetecan (ris‑rez) in a phase 3 trial for relapsed small‑cell lung cancer. The study e…